サクサク読めて、アプリ限定の機能も多数!
トップへ戻る
買ってよかったもの
www.merck.com
Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study October 1, 2021 6:00 am ET At the Interim Analysis, 7.3 Percent of Patients Who Received Molnupiravir Were Hospitalized Through Day 29, Compared With 1
Research The journey to invention and discovery is guided by science — and inspired by patients Patients We’re here to help you get the information you need to guide you on your health journey Investors Find our latest financials, events & presentations, news, stock information and investor contacts
このページを最初にブックマークしてみませんか?
『Merck | Home』の新着エントリーを見る
j次のブックマーク
k前のブックマーク
lあとで読む
eコメント一覧を開く
oページを開く